Forward-Looking Statements and Non-GAAP Financial Information

Some statements in this presentation are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks related to the proposed acquisitions of ImmunoGen and Cerevel, including the possibility that either or both of such acquisitions may not be consummated on the anticipated timeframe or at all, risks related to the ability to realize the anticipated benefits of the proposed acquisitions on the anticipated timeframe or at all, risks that the costs to consummate either or both acquisitions or to obtain the anticipated benefits of the proposed acquisitions could be greater than expected, the risk that an event occurs that could give rise to the right of AbbVie, on the one hand, or ImmunoGen or Cerevel, on the other hand, to terminate the acquisition agreements for such transactions, the risk that the businesses will not be integrated successfully, disruption from the proposed acquisitions making it more difficult to maintain business and operational relationships, the diversion of management’s attention from ongoing business operations and opportunities, negative effects of the consummation of the proposed acquisitions on business or employee relationships or the market price of the Company’s common stock and/or operating results, significant transaction costs, the assumption of unknown liabilities, the risk of litigation and/or regulatory actions related to the proposed acquisitions or ImmunoGen’s or Cerevel’s business, risks related to the financing of the proposed acquisitions, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s, ImmunoGen’s and Cerevel’s operations is set forth in Item 1A, “Risk Factors,” of AbbVie’s 2022 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information; Item 1A, “Risk Factors,” of ImmunoGen’s 2022 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that ImmunoGen subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information; and Item 1A, “Risk Factors,” of Cerevel’s 2022 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that Cerevel subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

This presentation is intended for the investor community only; materials are not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions.
AbbVie Long-Term Guidance

Expect total AbbVie sales to return to robust growth in 2025, with high-single digit CAGR through remainder of decade (2024 base year through 2029)

- On-Track

Skyrizi: >$17B in 2027 ($11.5B from PsO/PsA; $5.5B from IBD)  
Raised

Rinvoq: >$10B in 2027 ($4.5B from Rheum; $3.2B from IBD; $2.3B from Derm)  
Raised

Oncology revenue return to growth in 2026  
On-Track

Vraylar: Peak sales approaching $5B  
On-Track

Oral CGRPs (Ubrelvy & Qulipta): Peak sales >$3B combined  
Raised

ABBV-951: Peak sales >$1B  
On-Track

Aesthetics sales >$9B in 2029  
On-Track
Updated Skyrizi and Rinvoq Long-Term Guidance Based on Continuing Momentum for Both Brands

- Updated 2027 guidance for combined Skyrizi and Rinvoq is $6B above previous estimate
- Next wave of indications drive inflection for Rinvoq in 2027+
- Expect robust sales growth for Skyrizi and Rinvoq continuing into the 2030s

Rinvoq Rheum includes sales from approved rheumatoid arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis indications, as well as modest risk-adjusted sales from additional indications in late-stage development (giant cell arteritis approval anticipated in 2025; systemic lupus erythematosus approval anticipated in 2027). Rinvoq IBD includes sales from approved ulcerative colitis and Crohn’s disease indications. Rinvoq Derm includes sales from approved atopic dermatitis indication, as well as modest risk-adjusted sales from additional indications in late-stage development (vitiligo approval anticipated in 2026; hidradenitis suppurativa and alopecia areata approvals anticipated in 2027). Skyrizi Psoriatic Diseases includes sales from approved psoriasis and psoriatic arthritis indications. Skyrizi IBD includes sales from approved Crohn’s disease indication and risk-adjusted sales from ulcerative colitis indication, which is under regulatory review with approval anticipated in 2024.
# AbbVie R&D Pipeline

## Phase 1
- CUG-252* (IL-2 Mutein) SLE
- CLF065* (GLP-2 agonist) IBD
- ABBV-151 (GARP+TGFβ1) Solid Tumors
- ABBV-400 (c-Met ADC) Solid Tumors
- ABBV-706 (SEZ6 ADC) SCLC
- ABBV-181 (PD-1) Solid Tumors
- ABBV-CLS-579* (PTPN2) Solid Tumors
- ABBV-CLS-484* (PTPN2) Solid Tumors
- ABBV-514 (CCR8) Solid Tumors
- ABBV-319 (CD19/Steroid ADC) Heme Tumors
- ABBV-525 (MALT1) Heme Tumors
- CLBR001/SWI019* (sCAR-T) Heme Tumors
- ABBV-383 (CD3-BCMA) MM
- ABBV-453 (BCL-2) R/R MM t(11;14)
- Epkinly* (CD3-CD20) R/R CLL and Richter’s Syndrome
- ABBV-101 (BTK Degrader) R/R NHL
- ABBV-CLS-7262* (elF2B) VWM Disease
- ABBV-932 (D2/D3 Agonist) Bipolar Depression
- ABBV-903 (MPro Inhibitor) COVID
- IMGN-151‡ (FRα ADC) Ovarian Cancer
- IMNGC-936‡ (ADAM9 ADC) Solid Tumors
- Emraclidine# (M4 PAM) AD Psychosis
- CVL-354# (KOR Antagonist) MDD

## Phase 2
- Acazicolcept ALPN-101* (ICOS/CD28) SLE
- Lutikizumab (IL-1α/1β) HS
- ABBV-668 (RIPK1) UC
- OpSCF* (Stem Cell Factor mAb) AD
- Epkinly* (CD3-CD20) B-Cell NHL
- ABBV-400 (c-Met ADC) 2L CRC
- ABBV-151 (GARP+TGFβ1) 2L HCC
- TTX-030* (CD39) Pancreatic Cancer
- AL002* (TREM2) Alzheimer’s Disease
- ABBV-CLS-7262* (elF2B) ALS
- Elezanumab (RGA) Stroke
- Elezanumab (RGA) Spinal Cord Injury
- Onabata X (SNARE) Essential Tremor
- Onabata X (SNARE) Essential Tremor
- ABBV-RGX-314* (NAV AAV8 Anti-VEGF Fab) wAMD Suprachoroidal Delivery
- ABBV-RGX-314* (NAV AAV8 Anti-VEGF Fab) wAMD Suprachoroidal Delivery
- AGN-193408 (Prostamide 408 SR) Glaucome
- Armour Thyroid (T3T4) Hypothyroidism
- Botox (SNARE) IC/BPS
- ABBV-1882 (anti-PD1/anti-a4b7) HIV

## Registrational / Phase 3
- Rinoq (JAK 1) Alopecia Areata
- Rinoq (JAK 1) GCA
- Rinoq (JAK 1) HS
- Rinoq (JAK 1) SLE
- Rinoq (JAK 1) Vitiligo
- Imbruvica* (BTK) 1L FL
- Venclexta* (BCL-2) AML Post-Transplant
- Venclexta* (BCL-2) 3L+ MM t(11;14)
- Venclexta* (BCL-2): High Risk MDS
- Navitoclax (BCL-2/BCL-XL) Myelofibrosis
- Epkinly* (CD3-CD20) 1L DLBCL
- Epkinly* (CD3-CD20) R/R DLBCL
- Epkinly* (CD3-CD20) 1L FL
- Epkinly* (CD3-CD20) R/R FL
- Teliso-V (c-Met ADC) 2L+ NSCLC
- Botox (SNARE) Episodic Migraine Prevention
- BoNT/E (SNARE) Glabellar Lines
- Elahere‡ (FRα ADC) PSOC (PICCOLO)
- Elahere‡ (FRα ADC) PSOC (PICOLO)
- Elahere‡ (FRα ADC) PSOC (420)
- Pivekimab Sunirine‡ (CD123 ADC) BPDCN
- Emraclidine# (M4 PAM) Schizophrenia
- Tavapadon# (D1/D5 Partial Agonist) Parkinson’s Disease

## Submitted
- Skyrizi* (IL-23) UC
- Epkinly* (CD3-CD20) 3L+ FL
- ABBV-951 (dopamine receptor) Advanced Parkinson’s Disease (US)
- Botox (SNARE) Platysma Prominence (US)
- Botox (SNARE) Masseter Prominence (INTL)

---

As of February 2, 2024

Excludes devices in development; *AbbVie Partnered assets

‡ ImmunoGen Assets; #Cerevel Assets; 1,2 Closing of ImmunoGen and Cerevel acquisitions anticipated in mid-2024 subject to satisfaction or waiver of customary closing conditions
## AbbVie - Anticipated Key Pipeline Events

<table>
<thead>
<tr>
<th>Regulatory Approvals</th>
<th>2024</th>
<th>2025</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skyrizi UC</td>
<td></td>
<td>Rinvoq GCA</td>
</tr>
<tr>
<td>Epkinly 3L+ FL (AA)</td>
<td></td>
<td>Venclexa High Risk MDS</td>
</tr>
<tr>
<td>ABBV-951 Advanced PD (US)</td>
<td></td>
<td>Teliso-V 2L+ NSCLC (AA)</td>
</tr>
<tr>
<td>Botox Platysma Prominence (US)</td>
<td></td>
<td>Botox Episodic Migraine Prevention</td>
</tr>
<tr>
<td>Botox Masseter Prominence (INTL)</td>
<td></td>
<td>BoNT/E Glabellar Lines</td>
</tr>
</tbody>
</table>

### Regulatory Submissions

<table>
<thead>
<tr>
<th>Regulatory Submissions</th>
<th>2024</th>
<th>2025</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rinvoq GCA</td>
<td></td>
<td>Venclexa High Risk MDS</td>
</tr>
<tr>
<td>Teliso-V 2L+ NSCLC (AA)</td>
<td></td>
<td>Venclexa AML maintenance post transplant</td>
</tr>
<tr>
<td>Botox Episodic Migraine Prevention</td>
<td></td>
<td>Assuming closing of acquisition of Cerevel:</td>
</tr>
<tr>
<td>BoNT/E Glabellar Lines</td>
<td></td>
<td>Emraclidine® Schizophrenia</td>
</tr>
<tr>
<td><strong>Assuming closing of acquisition of ImmunoGen:</strong></td>
<td></td>
<td>Tavapadon® Parkinson’s Disease</td>
</tr>
<tr>
<td>Pivukimab Sunirine† 1L BPDCN</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Ph3/Registrational Data Readouts

<table>
<thead>
<tr>
<th>Ph3/Registrational Data Readouts</th>
<th>2024</th>
<th>2025</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rinvoq Ph3 GCA</td>
<td></td>
<td>Rinvoq Ph3 Alopecia Areata</td>
</tr>
<tr>
<td>Venclexa Ph3 High Risk MDS (VERONA)</td>
<td></td>
<td>Rinvoq Ph3 Vitiligo</td>
</tr>
<tr>
<td>Botox Ph3 Episodic Migraine Prevention</td>
<td></td>
<td>Venclexa Ph3 AML maintenance post transplant</td>
</tr>
</tbody>
</table>

### Assuming closing of acquisitions of ImmunoGen and Cerevel:

- Pivukimab Sunirine† Pivotal Ph2 1L BPDCN (CADENZA)
- Emraclidine® Pivotal Ph2 Schizophrenia
- Tavapadon® Ph3 Adjunctive Parkinson’s Disease (TEMPO-3)
- Tavapadon® Ph3 Monotherapy Parkinson’s Disease (TEMPO-1, TEMPO-2)

### Early-Stage POC Data Readouts

<table>
<thead>
<tr>
<th>Early-Stage POC Data Readouts</th>
<th>2024</th>
<th>2025</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV-400 Ph1 NSCLC and GEA</td>
<td></td>
<td>ABBV-668 Ph2 UC</td>
</tr>
<tr>
<td>ABBV-552 Ph2 Alzheimer’s Disease</td>
<td></td>
<td>ABBV-706 Ph1 SCLC</td>
</tr>
<tr>
<td>ABBV-CLS-7262 Ph2 ALS</td>
<td></td>
<td>ABBV-CLS-579 / 484 Ph1 Solid Tumors</td>
</tr>
<tr>
<td>Elezanumab Ph2 Stroke</td>
<td></td>
<td>Elezanumab Ph2 SCI</td>
</tr>
<tr>
<td>ABBV-RGX-314 Ph2 DR Suprachoroidal Delivery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABBV-RGX-314 Ph2 wAMD Suprachoroidal Delivery</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

As of February 2, 2024

AA = Accelerated Approval

†ImmunoGen Assets; #Cerevel Assets; †, # Closing of ImmunoGen and Cerevel acquisitions anticipated in mid-2024 subject to satisfaction or waiver of customary closing conditions
AbbVie’s Partnered Assets

- ABBV-CLS-579/484/7262 co-developed by Calico and AbbVie
- Acazicolcept (ALPN-101) developed by Alpine Immune Sciences through current Phase 2 study and AbbVie holds option for additional development
- AL002 developed by Alector through Phase 2 and AbbVie holds option for additional development
- Aztreonam/Avibactam co-developed by Pfizer and AbbVie
- CLBR001/SWI019 developed by Calibr in a first-in-patient trial and AbbVie holds option for additional development
- CLF065 developed by Scripps/Calibr in a first-in-patient trial and AbbVie holds option for additional development
- CUG-252 developed by Cugene through Phase 1b and AbbVie holds option for additional development
- Epkinly developed in partnership with Genmab
- Imbruvica jointly developed with Janssen Biotech
- OpSCF co-developed by Opsidio and AbbVie
- ABBV-RGX-314 co-developed by REGENXBIO and AbbVie
- Skyrizi developed in cooperation with Boehringer Ingelheim
- TTX-030 developed by Trishula Therapeutics through Phase 2 and AbbVie has option to lead global development
- Venclexta jointly developed with Roche
- Vraylar developed in cooperation with Gedeon Richter